Follow the bread crumb of dates...
Check Filing Date section. Then read Description section.
 This application is a continuation of U.S. application Ser. No. 15/759,148, filed Mar. 9, 2018, as a national phase application under 35 U.S.C. .sctn. 371 of International Application No. PCT/US2016/051847, filed Sep. 15, 2016, which claims the benefit of U.S. Provisional Application No. 62/218,990, filed on Sep. 15, 2015, the entirety of each of which is incorporated herein by reference.
Then ask how long it takes to file a patent that was filed back then? When do you think the discovery was made, and where?
That will tell why it was silly for Biotech to try and infer anything with ZIOP and royalties. I don't know if it is soft FUD (since he seems more tilted to PGEN) or just him not reading all the details and understanding timelines, that is causing him confusion as to why ZIOP not mentioned in it.
These patents are interesting from immunogeek perspective, and confirms what Cooper knows.
Bottom line is ZIOP has all they need to pursue TCR neoantigen as Cooper would like. No need to worry about this patent being negative in any way to ZIOP's goal. Rest easy.